New drug cocktail aims to stop kidney cancer comeback

NCT ID NCT05738694

Recruiting now Disease control Sponsor: ZHOU FANGJIAN Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether giving a combination of axitinib (a targeted therapy) and toripalimab (an immunotherapy) before surgery can help prevent kidney cancer from returning in high-risk patients. About 298 participants will either receive the drug combo followed by surgery, or surgery alone. The main goal is to see if the combo improves how long patients stay cancer-free after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axitinib plus toripalimab
What this could lead to: If successful, this combination could reduce the risk of kidney cancer returning after surgery, offering a new treatment option for high-risk patients.
What could go wrong: This is an early Phase 3 trial, so results are not yet known. The drugs may cause side effects like high blood pressure or immune reactions, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOADJUVANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOADJUVANT RENAL CELL CARCINOMA

Contacts and locations

Locations

Anhui Provincial Hospital
RECRUITING

Hefei, China
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, China
Fudan University Cancer Hospital
RECRUITING

Shanghai, China
Peking University First Hospital
RECRUITING

Beijing, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, China
The First Affiliated Hospital of Zhengzhou Hospital
RECRUITING

Zhengzhou, China
Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, China
West China Hospital
RECRUITING

Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.